Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire —
NEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of...